Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry

Kwon et al., Annals of Oncology, doi:10.1016/j.annonc.2021.01.067

Kwon et al., Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of.., Annals of Oncology, doi:10.1016/j.annonc.2021.01.067

Jan 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 5,211 prostate cancer patients, 799 on ADT, showing no significant differences in COVID-19 outcomes with treatment.

Important missing comments or errors? Let us know.

risk of death, 21.1% lower, RR 0.79, p = 1.00, treatment 1 of 799 (0.1%), control 7 of 4,412 (0.2%), NNT 2985.

risk of case, 17.6% higher, RR 1.18, p = 0.54, treatment 18 of 799 (2.3%), control 79 of 4,412 (1.8%), adjusted per study, odds ratio converted to relative risk, multivariable.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Kwon et al., 29 Jan 2021, retrospective, USA, peer-reviewed, 7 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Antiandrogens All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit